Source: Innovative Targeting Solutions Inc. & reported by https://www.firstwordpharma.com/
SAN FRANCISCO and VANCOUVER, Aug. 23, 2016 /CNW/ - Innovative Targeting Solutions Inc. (ITS) today announced a research collaboration with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Under the agreement, facilitated by Johnson & Johnson Innovation, the collaboration will utilize Innovative Targeting Solutions' proprietary HuTARG™ research platform to discover antibody candidates useful for modulating immune responses in autoimmunity or cancer. The HuTARG™ protein engineering platform is able to engineer both T-cell receptors and fully human antibodies that bind major histocompatibility complex (MHC)/peptide complexes displaying fragments of intracellular proteins of interest.
"Conventional biologic therapies do not target intracellular proteins which make up 60-80% of a cells proteome. The ability to target MHC/peptide complexes opens up an important untapped area for targeted therapy" said Paul Kang, CSO of Innovative Targeting Solutions Inc. "We are very excited to be working with Janssen in this exciting new area which we believe has the potential to transform the industry's ability to improve human health."
Read more: https://www.firstwordpharma.com/node/1410024?tsid=28®ion_id=4